A filter-based feature selection approach for identifying potential biomarkers for lung cancer

Background: Lung cancer is the leading cause of death from cancer in the world and its treatment is dependant on the type and stage of cancer detected in the patient. Molecular biomarkers that can characterize the cancer phenotype are thus a key tool in planning a therapeutic response. A common protocol for identifying such biomarkers is to employ genomic microarray analysis to find genes that show differential expression according to disease state or type. Data-mining techniques such as feature selection are often used to isolate, from among a large manifold of genes with differential expression, those specific genes whose differential expression patterns are of optimal value in phenotypic differentiation. One such technique, Biomarker Identifier (BMI), has been developed to identify features with the ability to distinguish between two data groups of interest, which is thus highly applicable for such studies. Results: Microarray data with validated genes was used to evaluate the utility of BMI in identifying markers for lung cancer. This data set contains a set of 129 gene expression profiles from large-airway epithelial cells (60 samples from smokers with lung cancer and 69 from smokers without lung cancer) and 7 genes from this data have been confirmed to be differentially expressed by quantitative PCR. Using this data set, BMI was compared with various well-known feature selection methods and was found to be more successful than other methods in finding useful genes to classify cancerous samples. Also it is evident that genes selected by BMI (given the same number of genes and classification algorithms) showed better discriminative power than those from the original study. After pathway analysis on the selected genes by BMI, we have been able to correlate the selected genes with well-known cancer-related pathways. Conclusions: Our results show that BMI can be used to analyze microarray data and to find useful genes for classifying samples. Pathway analysis suggests that BMI is successful in identifying biomarker-quality cancer-related genes from the data

PUEPro : A Computational Pipeline for Prediction of Urine Excretory Proteins

This work is supported by the National Natural Science Foundation of China (Grant Nos. 81320108025, 61402194, 61572227), Development Project of Jilin Province of China (20140101180JC) and China Postdoctoral Science Foundation (2014T70291).Postprin

A Machine Learning Framework for Identifying Molecular Biomarkers from Transcriptomic Cancer Data

Cancer is a complex molecular process due to abnormal changes in the genome, such as mutation and copy number variation, and epigenetic aberrations such as dysregulations of long non-coding RNA (lncRNA). These abnormal changes are reflected in transcriptome by turning oncogenes on and tumor suppressor genes off, which are considered cancer biomarkers. However, transcriptomic data is high dimensional, and finding the best subset of genes (features) related to causing cancer is computationally challenging and expensive. Thus, developing a feature selection framework to discover molecular biomarkers for cancer is critical. Traditional approaches for biomarker discovery calculate the fold change for each gene, comparing expression profiles between tumor and healthy samples, thus failing to capture the combined effect of the whole gene set. Also, these approaches do not always investigate cancer-type prediction capabilities using discovered biomarkers. In this work, we proposed a machine learning-based framework to address all of the above challenges in discovering lncRNA biomarkers. First, we developed a machine learning pipeline that takes lncRNA expression profiles of cancer samples as input and outputs a small set of key lncRNAs that can accurately predict multiple cancer types. A significant innovation of our work is its ability to identify biomarkers without using healthy samples. However, this initial framework cannot identify cancer-specific lncRNAs. Second, we extended our framework to identify cancer type and subtype-specific lncRNAs. Third, we proposed to use a state-of-the-art deep learning algorithm concrete autoencoder (CAE) in an unsupervised setting, which efficiently identifies a subset of the most informative features. However, CAE does not identify reproducible features in different runs due to its stochastic nature. Thus, we proposed a multi-run CAE (mrCAE) to identify a stable set of features to address this issue. Our deep learning-based pipeline significantly extended the previous state-of-the-art feature selection techniques. Finally, we showed that discovered biomarkers are biologically relevant using literature review and prognostically significant using survival analyses. The discovered novel biomarkers could be used as a screening tool for different cancer diagnoses and as therapeutic targets

Multiplatform biomarker identification using a data-driven approach enables single-sample classification

Background: High-throughput gene expression profiles have allowed discovery of potential biomarkers enabling early diagnosis, prognosis and developing individualized treatment. However, it remains a challenge to identify a set of reliable and reproducible biomarkers across various gene expression platforms and laboratories for single sample diagnosis and prognosis. We address this need with our Data-Driven Reference (DDR) approach, which employs stably expressed housekeeping genes as references to eliminate platform-specific biases and non-biological variabilities. Results: Our method identifies biomarkers with “built-in” features, and these features can be interpreted consistently regardless of profiling technology, which enable classification of single-sample independent of platforms. Validation with RNA-seq data of blood platelets shows that DDR achieves the superior performance in classification of six different tumor types as well as molecular target statuses (such as MET or HER2-positive, and mutant KRAS, EGFR or PIK3CA) with smaller sets of biomarkers. We demonstrate on the three microarray datasets that our method is capable of identifying robust biomarkers for subgrouping medulloblastoma samples with data perturbation due to different microarray platforms. In addition to identifying the majority of subgroup-specific biomarkers in CodeSet of nanoString, some potential new biomarkers for subgrouping medulloblastoma were detected by our method. Conclusions: In this study, we present a simple, yet powerful data-driven method which contributes significantly to identification of robust cross-platform gene signature for disease classification of single-patient to facilitate precision medicine. In addition, our method provides a new strategy for transcriptome analysis

A multiple-filter-multiple-wrapper approach to gene selection and microarray data classification

Filters and wrappers are two prevailing approaches for gene selection in microarray data analysis. Filters make use of statistical properties of each gene to represent its discriminating power between different classes. The computation is fast but the predictions are inaccurate. Wrappers make use of a chosen classifier to select genes by maximizing classification accuracy, but the computation burden is formidable. Filters and wrappers have been combined in previous studies to maximize the classification accuracy for a chosen classifier with respect to a filtered set of genes. The drawback of this single-filter-single-wrapper (SFSW) approach is that the classification accuracy is dependent on the choice of specific filter and wrapper. In this paper, a multiple-filter-multiple-wrapper (MFMW) approach is proposed that makes use of multiple filters and multiple wrappers to improve the accuracy and robustness of the classification, and to identify potential biomarker genes. Experiments based on six benchmark data sets show that the MFMW approach outperforms SFSW models (generated by all combinations of filters and wrappers used in the corresponding MFMW model) in all cases and for all six data sets. Some of MFMW-selected genes have been confirmed to be biomarkers or contribute to the development of particular cancers by other studies. © 2006 IEEE.published_or_final_versio

Test on Existence of Histology Subtype-Specific Prognostic Signatures Among Early Stage Lung Adenocarcinoma and Squamous Cell Carcinoma Patients Using a Cox-Model Based Filter

BACKGROUND: Non-small cell lung cancer (NSCLC) is the predominant histological type of lung cancer, accounting for up to 85% of cases. Disease stage is commonly used to determine adjuvant treatment eligibility of NSCLC patients, however, it is an imprecise predictor of the prognosis of an individual patient. Currently, many researchers resort to microarray technology for identifying relevant genetic prognostic markers, with particular attention on trimming or extending a Cox regression model. Adenocarcinoma (AC) and squamous cell carcinoma (SCC) are two major histology subtypes of NSCLC. It has been demonstrated that fundamental differences exist in their underlying mechanisms, which motivated us to postulate the existence of specific genes related to the prognosis of each histology subtype. RESULTS: In this article, we propose a simple filter feature selection algorithm with a Cox regression model as the base. Applying this method to real-world microarray data identifies a histology-specific prognostic gene signature. Furthermore, the resulting 32-gene (32/12 for AC/SCC) prognostic signature for early-stage AC and SCC samples has superior predictive ability relative to two relevant prognostic signatures, and has comparable performance with signatures obtained by applying two state-of-the art algorithms separately to AC and SCC samples. CONCLUSIONS: Our proposal is conceptually simple, and straightforward to implement. Furthermore, it can be easily adapted and applied to a range of other research settings. REVIEWERS: This article was reviewed by Leonid Hanin (nominated by Dr. Lev Klebanov), Limsoon Wong and Jun Yu

Dissimilarity-based representation for radiomics applications

Radiomics is a term which refers to the analysis of the large amount of quantitative tumor features extracted from medical images to find useful predictive, diagnostic or prognostic information. Many recent studies have proved that radiomics can offer a lot of useful information that physicians cannot extract from the medical images and can be associated with other information like gene or protein data. However, most of the classification studies in radiomics report the use of feature selection methods without identifying the machine learning challenges behind radiomics. In this paper, we first show that the radiomics problem should be viewed as an high dimensional, low sample size, multi view learning problem, then we compare different solutions proposed in multi view learning for classifying radiomics data. Our experiments, conducted on several real world multi view datasets, show that the intermediate integration methods work significantly better than filter and embedded feature selection methods commonly used in radiomics.Comment: conference, 6 pages, 2 figure